Meeting NewsVideo

VIDEO: ‘Exciting times’ for Ocular Therapeutix

SAN FRANCISCO — At the Ophthalmology Innovation Summit preceding the American Academy of Ophthalmology meeting, Antony Mattessich, CEO of Ocular Therapeutix, discusses Dextenza (dexamethasone ophthalmic insert 0.4 mg) as well as some of the company’s phase 1 programs.

SAN FRANCISCO — At the Ophthalmology Innovation Summit preceding the American Academy of Ophthalmology meeting, Antony Mattessich, CEO of Ocular Therapeutix, discusses Dextenza (dexamethasone ophthalmic insert 0.4 mg) as well as some of the company’s phase 1 programs.

    See more from Ophthalmology Innovation Summit